NCT05274048View on ClinicalTrials.gov

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Gastric CancerGastrointestinal CancerHER2 Gene Mutation
Interventions
DRUG

Neratinib Pill

Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)

DRUG

Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle

Trial Locations (3)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

94304

RECRUITING

Stanford Cancer Center, Palo Alto

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Puma Biotechnology, Inc.

INDUSTRY

lead

Fox Chase Cancer Center

OTHER